Valneva SE
HealthcareNASDAQ:VALN · NASDAQ Global Select
+$0.07 today
Vol 0.02M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-108.5%
avg -41.9%
ROIC
-25.0%
avg -12.5%
ROA
-28.9%
avg -12.4%
Analysis
ROIC is currently the strongest return metric at -25.0% versus its period average of -12.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas Lingelbach | President, Chief Executive Officer & Director | $1.10M | — | 63 | — | — |
Peter Buhler | Chief Financial Officer | $448,797.00 | — | 55 | — | — |
Juan-Carlos Jaramillo | Chief Medical Officer | $434,394.00 | — | 54 | — | — |
Dipal Patel | Chief Commercial Officer | $387,779.00 | — | 51 | — | — |
Kendra Wergin | General Counsel & Corporate Secretary | — | — | 39 | — | — |
Hanneke Schuitemaker | Chief Scientific Officer | — | — | 61 | — | — |
Joshua Drumm | Vice President of Investor Relations | — | — | — | — | — |
Vincent Dequenne | Chief Operating Officer | — | — | 59 | — | — |
Laetitia Bachelot-Fontaine | Vice President of Global Communications & European Investor Relations | — | — | — | — | — |
Petra Pesendorfer | Chief People Officer | — | — | 40 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +183.7% | +12.3% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +183.7% over three years. Forward estimates point to Revenue at +12.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Geron Corporation
NASDAQ:GERN
$737.75M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Who manages VALN?
Valneva SE (VALN) lists 10 active executives. The top listed executive is Juan-Carlos Jaramillo, Chief Medical Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.